How to prevent Chemotherapy Induced Cardiotoxicity

5 November 2018

Organised by:

Anticancer drugs can induce cardiotoxicity; the dilated cardiomyopathy secondary to chemotherapy is more insidious than various cardiomyopathies: 40% of the patients under anthracyclines treatment manifest ventricular arrhythmias, 5% of them manifest left ventricular systolic dysfunction and Congestive Heart Failure. For these patients at high cardiotoxic risk it is therefore very important to prevent cardiovascular damage.

References

Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Silber JH, Cnaan A, Clark BJ, et al. - Am Heart J 2001;142(4):577-585

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis
Gharib MI, Burnett AK- European Journal of Heart Failure 4 (2002) 235-242

Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated.
Iarussi D, Indolfi P, Pisacane C, et al. - Am J Cardiol. 2003 Aug 1;92(3):359-61

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD.
J Clin Oncol 2005;23:2629–2636

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition
Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM
Circulation 2006;114:2474–2481

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
Eschenhagen T et al.- European Journal of Heart Failure (2011) 13, 1–10

Individualised prevention of anthracycline-induced cardiotoxicity in cancer treatment
Greco E, Greco R- E-journal of Cardiology Practice, Vol 10, N° 30, 04 Jun 2012